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Abstract. 
 
The small GTPase ADP-ribosylation factor 
(ARF) is absolutely required for coatomer vesicle for-
mation on Golgi membranes but not for anterograde 
transport to the 
 
medial
 
-Golgi in a mammalian in vitro 
transport system. This might indicate that the
 
 
 
in vivo 
mechanism of intra-Golgi transport is not faithfully 
reproduced in vitro, or that intra-Golgi transport occurs 
by a nonvesicular mechanism. As one approach to dis-
tinguishing between these possibilities, we have char-
acterized two additional cell-free systems that recon-
stitute transport to the 
 
trans-
 
Golgi (
 
trans
 
 assay) and 
 
trans
 
-Golgi network (TGN assay). Like in vitro trans-
port to the 
 
medial
 
-Golgi (
 
medial
 
 assay), transport to 
the 
 
trans
 
-Golgi and TGN requires cytosol, ATP, and 
 
N
 
-ethylmaleimide–sensitive fusion protein (NSF). 
However, each assay has its own distinct characteristics 
of transport. The kinetics of transport to late compart-
ments are slower, and less cytosol is needed for gua-
nosine-5
 
9
 
-
 
O
 
-(3-thiotriphosphate) (GTP
 
g
 
S) to inhibit 
transport, suggesting that each assay reconstitutes a dis-
tinct transport event. Depletion of ARF from cytosol 
abolishes vesicle formation and inhibition by GTP
 
g
 
S, 
but transport in all assays is otherwise unaffected. Puri-
fied recombinant myristoylated ARF1 restores inhibi-
tion by GTP
 
g
 
S, indicating that the GTP-sensitive com-
ponent in all assays is ARF. We also show that 
asymmetry in donor and acceptor membrane proper-
ties in the 
 
medial
 
 assay is a unique feature of this assay 
that is unrelated to the production of vesicles. These 
findings demonstrate that characteristics specific to 
transport between different Golgi compartments are 
reconstituted in the cell-free system and that vesicle 
formation is not required for in vitro transport at any 
level of the stack.
 
M
 
uch
 
 of what is known about transport within the
Golgi complex has come from the analysis of a
cell-free system that reconstitutes a single step
in the intra-Golgi transport of vesicular stomatitis viral
glycoprotein (VSV-G protein)
 
1
 
 (2). This system is believed
to measure transport between the 
 
cis
 
 and 
 
medial
 
 compart-
ments of two distinct populations of Golgi-enriched mem-
branes. The “donor” Golgi population is isolated from
cells that are deficient in 
 
N
 
-acetylglucosaminyl (GlcNAc)
transferase I activity and that have been infected with ve-
sicular stomatitis virus. The “acceptor” Golgi population is
prepared from uninfected wild-type cells containing the func-
tional enzyme. When donor and acceptor membranes are
incubated at physiological temperature with cytosol, ATP,
and UDP-GlcNAc, VSV-G protein from donor membranes
is mobilized and subsequently glycosylated by acceptor-
derived GlcNAc transferase I. This system has been exten-
sively used to analyze the mechanism of intra-Golgi trans-
port and to identify numerous factors required for transport
(for review see reference 49). From these studies, a model
has been proposed in which coated vesicles transport an-
terograde-directed protein cargo between the individual
cisternae of the Golgi complex (for review see reference 50).
The small GTPase ADP-ribosylation factor (ARF) plays
a central role in the coated vesicle transport hypothesis.
ARF is required for coated vesicle formation on Golgi cis-
ternae (40, 56). In addition, constitutive activation of ARF
by the slowly hydrolyzable analogue of GTP, guanosine-
5
 
9
 
-
 
O
 
-(3-thiotriphosphate) (GTP
 
g
 
S), results in the accumu-
lation of nonfunctional Golgi vesicles (35, 58) and inhibits
in vitro Golgi transport (35, 55). From these and other
findings, a model for ARF as the initiator of vesicle forma-
tion has been proposed (for review see reference 6). Initia-
tion requires the interaction of soluble ARF-GDP with a
 
Address all correspondence to Peggy Weidman, Department of Biochem-
istry and Molecular Biology, Saint Louis University School of Medicine,
St. Louis, MO 63104. Tel.: 314-577-8179. Fax: 314-577-8156. E-mail:
weidmanp@wpogate.slu.edu
 
1. 
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GIC, endoplasmic reticulum–Golgi intermediate compartment; GlcNAc,
 
N
 
-acetylglucosamine; GTP
 
g
 
S, guanosine-5
 
9
 
-
 
O
 
-(3-thiotriphosphate); ME-
SNA, 2-mercaptoethanesulfonic acid; myr-rARF1, recombinant myristoy-
lated ARF1; NEM, 
 
N
 
-ethylmaleimide; non-myr-rARF1, recombinant
nonmyristoylated ARF1; NSF, NEM-sensitive fusion protein; STI, soy-
bean trypsin inhibitor; VSV-G protein, vesicular stomatitis viral glycoprotein.
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brefeldin A–sensitive exchange factor, exchange of GDP
for GTP, and association of ARF with the Golgi mem-
brane (17, 20). ARF-GTP then recruits a cytosolic coat
protein complex, coatomer (16, 43) or the adaptor AP-1
(52, 57), to the membrane, possibly through activation of a
Golgi-associated phospholipase D (32). Assembly of the
coat proteins causes deformation of the membrane to
form a coated bud, which pinches off to form a coated ves-
icle containing protein to be transported. Hydrolysis of
ARF-bound GTP is required for subsequent disassembly
of the coat before
 
 
 
vesicle fusion with the target membrane
(54). GTP
 
g
 
S prevents nucleotide hydrolysis by ARF,
thereby blocking vesicle uncoating and leading to exces-
sive accumulation of coated vesicles (35, 58). 
Although this model for ARF function in vesicle forma-
tion is compelling, the relationship between ARF-induced
vesicle formation and intra-Golgi transport is less certain.
A reexamination of ARF-GTP
 
g
 
S–induced (35) and ARF
NH
 
2
 
-terminal peptide–induced (30) inhibition of in vitro
Golgi transport has provided evidence for an inhibitory
mechanism involving induction of generalized Golgi mem-
brane disfunction, rather than specific inhibition of trans-
port per se (58, 60). Moreover, the vesicular transport hy-
pothesis is seemingly in contradiction with the observation
that ARF is not required for cell-free Golgi transport (18,
56). Only one distinction has been discovered between in
vitro transport in the presence or absence of ARF. When
ARF is present and vesicles are formed, glycosylation-incom-
petent Golgi compete with wild-type acceptor Golgi for
transported VSV-G protein, as expected for vesicular
transport (18). In contrast, no competition is observed in
the absence of ARF and vesicles, suggesting that cisternae
fuse and their enzyme contents mix. This finding led to the
proposal that transport is vesicular when vesicles are
formed and then switches to direct fusion of cisternae in
the absence of vesicles (18). 
There are at least two alternative hypotheses that are
also consistent with this and all other in vitro
 
 
 
transport data.
One is that this particular in vitro transport assay may ac-
tually measure fusion between the 
 
cis
 
-Golgi and transport
intermediates derived from endoplasmic reticulum vesi-
cles (ERGIC) that have matured beyond the stage that re-
quires ARF and coat proteins (56). Removal of ARF might
cause Golgi cisternae to fuse with one another, abolishing
the competition for fusion with ERGIC donor membranes.
However, the mechanism of transport from ERGIC to
Golgi would be otherwise unaffected. An alternative hy-
pothesis is that transport may occur via transient tubular
connections between cisternae (59). For example, tubules
extending from one cisterna could fuse with another cis-
terna. Scission of a tubule close to the originating cisterna
would result in transfer of the tubule and its contents to
the second cisterna and would also prevent mixing of
Golgi resident enzymes. Although ARF may be required
to initiate tubule formation in vivo
 
 
 
(59), transport could be
ARF independent in vitro
 
 
 
if preexisting tubules on the iso-
lated Golgi cisternae can participate in transport. On the
other hand, if ARF is also required
 
 
 
for tubule scission, re-
moval of ARF would allow mixing of cisternal enzymes
during the in vitro reaction.
As one approach to distinguish between these various
hypotheses, we have characterized two additional intra-
Golgi transport assays that measure transport to the 
 
trans
 
-
Golgi and the TGN (48). If the original assay is in fact
measuring fusion of ERGIC with the 
 
cis
 
-Golgi, then trans-
port to later Golgi compartments might require vesicles
and exhibit distinct characteristics. On the other hand, if
the mechanism of transport at all levels of the stack is the
same, then the characteristics of transport to all Golgi com-
partments should be similar. Here we show that the char-
acteristics of in vitro transport to late Golgi compartments
are distinct from those of transport to early Golgi com-
partments. Despite these distinctions, ARF is not required
for in vitro transport to any compartment within the Golgi,
and no evidence was found for a switch in the mechanism
of transport upon removal of ARF.
 
Materials and Methods
 
Reagents
 
UMP-kinase, 
 
N
 
-ethylmaleimide (NEM), and 2-mercaptoethanesulfonic
acid (MESNA) were purchased from Sigma Chemical Co. (St. Louis, MO).
GTP
 
g
 
S and ATP-regeneration system components were purchased from
Boehringer Mannheim Corp. (Indianapolis, IN). Tritiated nucleotide sug-
ars were purchased either from Amersham Life Science (Cleveland, OH),
New England Nuclear (Boston, MA), or American Radiolabeled Chemi-
cals (St. Louis, MO). Protein concentrations were determined by BCA
protein assay using BSA standards (Pierce Chemical Co., Rockford, IL).
Anti-ARF antibody and myristoylated recombinant ARF1 were kind gifts
of R. Kahn (Department of Biochemistry, Emory University, Atlanta,
GA). Nonmyristolyated recombinant ARF1 was a kind gift of Scott
Berger and Paul Melançon (Department of Cell Biology and Anatomy,
University of Alberta, Canada).
 
Cell Culture and Biological Materials
 
CHO wild-type (Pro
 
2
 
5
 
) and mutant cell lines Lec 1 (defective in GlcNAc
transferase I; reference 53), Lec 8 (defective in UDP-galactose translocase;
references 14, 53), and Lec 2 (defective in CMP-sialic acid translocase; ref-
erences 15, 53) were purchased from American Type Culture Collection
(Rockville, MD) and cultured in suspension with 
 
a
 
-MEM, 7% Fetalclone
II serum (Hyclone Laboratories, Logan, UT), and penicillin/streptomycin
(GIBCO BRL, Gaithersburg, MD). Donor membranes were prepared
from each mutant cell line after infection with VSV, as previously de-
scribed (10). Acceptor membranes were prepared from uninfected wild-
type cells. Golgi-enriched membranes were prepared from the cell homo-
genates by sucrose density flotation (2). CHO cytosol was prepared from
homogenates of wild-type or Lec 1 cells as described (5) without the NEM-
sensitive fusion protein (NSF) inactivation step. Bovine brain cytosol was
prepared according the method of Clary and Rothman (9). CHO and bo-
vine brain cytosols were essentially interchangeable in all assays. Cytosol
buffer consists of 10 mM Tris, pH 7.4, 50 mM KCl, and 1 mM DTT.
 
Intra-Golgi Transport Assays
 
The basic components of each 25-
 
m
 
l transport reaction were 25 mM
Hepes, pH 7.4, 2.5 mM Mg acetate, 20 mM KCl, an ATP-regeneration sys-
tem (50 
 
m
 
M ATP, 250 
 
m
 
M UTP, 5 mM creatine phosphate, 8 IU/ml creatine
phosphokinase), 10 
 
m
 
M palmitoyl-CoA, 2.5 
 
m
 
l acceptor membranes (
 
z
 
60
 
m
 
g/ml final), and 2.5–10 
 
m
 
l cytosol (CHO 
 
5 
 
0.5–2 mg/ml final, bovine
brain 
 
5 
 
1.2–4.8 mg/ml final). In addition to the basic components, the 
 
me-
dial
 
 assay also contained 2.5–5 
 
m
 
Ci/ml UDP-[
 
3
 
H]GlcNAc and 2.5 
 
m
 
l Lec 1
donor membranes (
 
z
 
60 
 
m
 
g/ml) and was incubated at 37°C for 60–80 min. 
In addition to the basic components, the 
 
trans
 
 assay also contained 20
 
m
 
Ci/ml UDP-[
 
3
 
H]galactose, 2.5 
 
m
 
l Lec 8 donor membranes (
 
z
 
60 
 
m
 
g/ml), 1
mg/ml soybean trypsin inhibitor (STI), and 10 
 
m
 
M MnCl
 
2 
 
and was incu-
bated at 37°C for 90 min. Galactosyl transferase has an absolute require-
ment for Mn
 
2
 
1
 
 (21), and inclusion of Mn
 
2
 
1
 
 in this assay increased the
incorporation of [
 
3
 
H]Gal into VSV-G protein by three- to fourfold. Al-
though 30 mM Mn
 
2
 
1
 
 can induce cytosol and ATP-independent fusion of
Golgi membranes (42), transport in this assay was absolutely cytosol- and
ATP-dependent at 10 
 
m
 
M Mn
 
2
 
1
 
.  
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In addition to the basic components, the TGN assay also contained 6
 
m
 
Ci/ml CMP-[
 
3
 
H]sialic acid, 2.5 
 
m
 
l Lec 2 donor membranes (
 
z
 
60 
 
m
 
g/ml),
and 1 mg/ml STI and was incubated at 37°C for 2.5 h. It has previously
been reported that optimal in vitro transport to the TGN requires higher
concentrations of Mg
 
2
 
1
 
 and DTT than present in the 
 
medial
 
 assay (48). In
our hands, no stimulatory effect of Mg
 
2
 
1
 
 was observed in the TGN assay,
and DTT was found to inhibit incorporation of sialic acid into VSV-G pro-
tein. Addition of STI to the 
 
trans
 
 and TGN assays appeared to stabilize
the membranes during the longer incubations, resulting in a 1.2–1.4 fold
increase in the incorporation of labeled sugar. At the end of a transport
incubation, VSV-G protein was immunoprecipitated as previously de-
scribed (2). Immune complexes were collected by filtration, and incorpo-
ration of tritiated label was quantitated by scintillation counting. 
 
Two-Stage Kinetic Assays
 
The two-stage kinetic assay was a modification of the method of Hiebsch
and Wattenberg (28), where transport is allowed to occur in the absence
of nucleotide sugar in the first stage, and then the transported protein is
glycosylated in a second stage incubation. In the 
 
trans
 
 and TGN assays, we
found it necessary to allow initiation of glycosylation during the first stage
of the assay to obtain complete glycosylation of transported protein in the
second stage. In the modified assay, the first stage consisted of a large trans-
port reaction mixture containing the appropriate nucleotide-[
 
3
 
H]sugar,
ATP mix, cytosol, and membranes that was incubated at 37°C to permit
transport. At various times, transport was stopped by removing 25 
 
m
 
l of
reaction mixture, diluting it 1:4 with 25 mM Hepes, pH 7.4, and 0.3 M su-
crose at room temperature, and collecting the membranes by centrifuga-
tion at 16K rpm in a microfuge at room temperature for 2.5 min. The su-
pernatant was withdrawn, and the membrane pellet was covered with
glycosylation buffer (25 mM Hepes, pH 7.4, 20 mM KCl, 2.5 mM Mg
(OAc)
 
2
 
, ATP-regenerating system, 0.2 mg/ml UMP-kinase, 0.3 M sucrose,
and appropriate nucleotide-[
 
3
 
H-]sugar). The incubation was then contin-
ued at 37°C for a total of 60, 90, or 150 min for the 
 
medial
 
, 
 
trans
 
, and TGN
assays, respectively, to allow complete glycosylation of the VSV-G protein
transported in the first stage of the reaction. In the absence of a first stage
incubation or when cytosol was omitted from the first incubation, no in-
corporation of [
 
3
 
H]sugar was obtained in the second stage. The maximum
incorporation of label in the modified two-stage assay was identical to that
obtained in a normal one-stage transport incubation.
 
Preparation of ARF-depleted Cytosol
 
ARF was removed from CHO or bovine brain cytosol by anion exchange
chromatography. Desalted cytosol (at 4–6 mg/ml for CHO or 10–12 mg/ml
for bovine brain, in 10 mM Tris, pH 7.4, at room temperature, 50 mM KCl,
and 1 mM DTT) was diluted in TD buffer (10 mM Tris, pH 7.4, 1 mM
DTT) containing 25 
 
m
 
M EDTA to give 10 
 
m
 
M EDTA and 20 mM KCl after
dilution. This was loaded in the cold onto a Fast-Flow Q anion exchange
matrix (Pharmacia Biotech, Piscataway, NJ), such that the protein/matrix
ratio was 
 
z
 
0.9 mg/ml. The column was washed with TD buffer containing
20 mM KCl and 10 
 
m
 
M EDTA. The unbound protein constituted ARF-
depleted pool I. ARF was eluted from the column with TD buffer contain-
ing 65 mM KCl and 1 mM MgCl
 
2
 
. The remaining protein was eluted with
500 mM KCl in TD buffer. This constituted ARF-depleted pool II. ARF-
depleted pools I and II were combined, concentrated to approximately
half the original volume of starting cytosol in either an Amicon pressure
cell (Danvers, MA) with a YM10 membrane or a centrifugal ultrafilter
(model Centricel 20, 10,000 MW cutoff; Polysciences, Warrington, PA),
and desalted on disposable desalting columns (Bio-Rad Laboratories, Her-
cules, CA). The ARF-containing pool was similarly concentrated to half
the original volume of starting cytosol. Therefore, 1 
 
m
 
l starting cytosol was
equivalent to 0.5 
 
m
 
l ARF-depleted cytosol plus 0.5 
 
m
 
l ARF-containing
pool. The amount of ARF in each pool was determined after SDS-PAGE
(15% acrylamide) by Western blotting with 1D9 mouse monoclonal anti-
body directed against all human isoforms of ARF (8), using rabbit anti–
mouse IgG peroxidase and chemiluminescent reagent from Pierce Chem-
cial Co. for detection.
 
NEM Sensitivity Assays
 
The sensitivity of membranes to NEM was measured by preincubating
either donor or acceptor membranes alone in a 25-
 
m
 
l standard transport
reaction mixture containing NEM at concentrations ranging from 0 to 1 or
2 mM. Reactions were preincubated for 15 min at room temperature, and
then unreacted NEM was quenched with 2 or 4 mM MESNA. The com-
plementary untreated membrane, in a 25-
 
m
 
l standard reaction mixture,
was added to provide NSF, other NEM-sensitive cytosolic components,
and a functional membrane partner for transport. The incubation was
continued as described for a normal transport reaction.
 
NSF-dependent Transport to the medial-Golgi with 
CHO Lec 8 and Lec 2 Donors
 
Lec 8 and Lec 2 donor membranes contain functional GlcNAc transferase
I and, therefore, are capable of incorporating GlcNAc into VSV-G pro-
tein that already resides in the 
 
medial
 
 compartment. This can give rise to
transport-independent incorporation of GlcNAc into VSV-G protein al-
ready residing in the 
 
medial
 
 compartment (56). To specifically measure
transport to the 
 
medial
 
-Golgi by incorporation of 
 
3
 
H-GlcNAc, we took
advantage of the NSF dependence of transport. The rate, NEM sensitivity,
and GTP
 
g
 
S sensitivity of transport to the 
 
medial-
 
Golgi were measured in
transport reactions containing UDP-[
 
3
 
H]GlcNAc and either CHO Lec 8
or Lec 2 donor membranes in the presence or absence of NSF. NSF was
selectively inactivated by NEM pretreatment of both donor and acceptor
membranes on ice, as previously described (5). The amount of VSV-G
protein transported was determined from the total [
 
3
 
H]GlcNAc incorpo-
rated into VSV-G protein with NSF, less the amount incorporated in the
absence of NSF. Similar experiments were performed using CHO Lec 2
donor membranes (containing active galactosyl translocase) to measure
NSF-dependent transport to the 
 
trans
 
-Golgi by incorporation of [
 
3
 
H]ga-
lactose.
 
Electron Microscopy
 
Transmission electron microscopy of replicas from quick-frozen, vacuum-
dried Golgi membranes was carried out as previously described (56, 58,
60). Briefly, freshly isolated Golgi membranes were attached to polyly-
sine- and glutaraldehyde-treated coverslips and subjected to
 
 
 
in vitro trans-
port incubations for 15 min at 37°C with various preparations of bovine
cytosol and purified recombinant ARF1. Carbon and platinum replicas of
the membranes were prepared after fixation, quick freezing, and vacuum
drying. Replicas were viewed in a transmission electron microscope, and
20–40 micrographs at 20,000–33,000 magnification were taken of each
sample. The micrographs were numbered and randomized for measure-
ment of the area encompassed by the Golgi membranes and the numbers
of buds and vesicles with or without a punctate coating (coated or un-
coated), as previously described (56, 58). The micrographs were also
scored for the number of cisternae per micrograph, the number and esti-
mated average size of fenestrae in each cisternae, and the presence of long
(
 
.
 
100 nm) blunt-ended tubules extending from the periphery of cisternae.
The range of fenestrae sizes were determined from measurements taken
from five representative micrographs for each size class. The randomized
data were entered into a computer plotting program (Deltagraph 4.0;
Deltapoint, Monterey, CA), sorted, and the various parameters computed
for each sample. 
 
Results
 
Cell-free Transport to Three
Distinct Golgi Compartments Displays Similar
Biochemical Requirements
 
We have characterized two cell-free transport assays that
measure transport to either the 
 
trans
 
-Golgi or the TGN.
These assays are based on the original in vitro Golgi trans-
port assay that is believed to reconstitute transport to the
 
medial
 
 compartment (the 
 
medial
 
 assay; reference 2). In
this assay, transport between GlcNAc transferase–deficient
VSV-infected donor membranes and uninfected wild-type
acceptor membranes is measured by the incorporation of
labeled GlcNAc into the carbohydrate chains of VSV-G
protein. To measure transport from the medial-Golgi to
the trans-Golgi (the trans assay), VSV-infected donor mem-
branes were prepared from CHO Lec 8 cells, which lack
UDP-galactose translocase activity (14). In the absence ofThe Journal of Cell Biology, Volume 140, 1998 514
this activity, UDP-galactose cannot be transported into
the Golgi lumen, where it normally serves as substrate for
the predominantly trans-Golgi enzyme, galactose trans-
ferase (14, 46, 47). As a result, Lec 8 donor Golgi are un-
able to add galactose to the carbohydrate chains on VSV-G
protein. When wild-type acceptor membranes are coincu-
bated with Lec 8 donor membranes, however, VSV-G can
be transported from the medial donor Golgi compartment
to the trans compartment of the acceptor, which contains
the active translocase. By the inclusion of UDP-[3H]galac-
tose, the amount of protein transported can be quantified
by incorporation of [3H]galactose into VSV-G protein. 
A similar assay for transport from the trans-Golgi to the
TGN (the TGN assay) was employed using donor Golgi iso-
lated from VSV-infected CHO Lec 2 cells that lack CMP–
sialic acid translocase activity (15). By the same principle
as the trans assay, transport was detected by coincubating
Lec 2 donor membranes with wild-type acceptor mem-
branes in the presence of CMP-[3H]sialic acid (48) and mea-
suring incorporation of [3H]sialic acid into VSV-G protein.
Unlike the medial assay, where VSV-G protein in the do-
nor ERGIC could acquire GlcNAc upon delivery to the
cis acceptor compartment in vitro (51), transport in these
new assays is strictly intra-Golgi. This is because incorpo-
ration of GlcNAc into VSV-G protein carbohydrates, a
Golgi-specific modification, is a prerequisite for the addi-
tion of galactose (31) in the assay. Since UDP-GlcNAc is
not present in the incubation, only VSV-G protein that has
reached the medial-Golgi and acquired GlcNAc in vivo
can serve as substrate for addition of galactose in vitro.
Likewise, incorporation of sialic acid requires that the
VSV-G protein carbohydrates already contain galactose,
and that the protein has, therefore, reached the trans-
Golgi  in vivo.
The requirements for transport to the trans compart-
ment and the TGN demonstrate a fundamental similarity
to those for transport to the medial compartment. All as-
says required ATP and an ATP-regenerating system. In
addition, cytosolic protein in the range of 0.5–1.0 mg/ml
was necessary to observe optimal transport of VSV-G pro-
tein. Some preparations of cytosol were inhibitory at high
concentrations in the assays. This was largely due to the
suppression of glycosylation of VSV-G protein after trans-
port, rather than inhibition of transport per se (not shown).
Although not required for transport, 10 mM palmitoyl-
coenzyme A, a purported vesicle fission and fusion agent
(44, 45), stimulated transport in all three assays (not shown).
As would be expected for processes involving targeted
membrane fusion events, transport in all three systems
also required the fusion protein NSF (not shown; refer-
ence 5). These data suggest that in vitro transport through-
out the Golgi complex requires the regulated interaction
and eventual fusion of membranes.
The Characteristics of Transport to Each Golgi 
Compartment Are Distinct
Despite the similarities in general requirements, transport
in the medial, trans, and TGN assays exhibits unique char-
acteristics. For example, the rate of overall glycosylation-
coupled transport to the trans-Golgi is slower than to the
medial compartment, and even slower still to the TGN com-
partment (Table I). Since glycosylation of VSV-G protein
is the rate-limiting step of the medial assay (28), we also
measured the rate of transport independent of glycosyla-
tion using a two-stage kinetic assay. In the first stage, do-
nor and acceptor membranes were incubated at 37°C with
cytosol, ATP, and radiolabeled nucleotide sugar to allow
transport and glycosylation to occur. At various times, the
membranes were reisolated and incubated in a second stage
under conditions that promote glycosylation of VSV-G
protein that had been transported, while prohibiting fur-
ther transport (see Materials and Methods). Analysis of
the rates of transport using this two-stage kinetics assay
demonstrates that the rate of transport to the trans-Golgi
is substantially slower than transport to the medial com-
partment, and transport to the TGN is slower yet (Table
I). Thus, each assay exhibits a characteristic rate of trans-
port, as well as rate of transport-coupled glycosylation.
We also tested for asymmetry in the properties of the
donor and acceptor membranes in each assay. The donor
membranes in the medial assay are known to be more sen-
sitive to irreversible inactivation by NEM than acceptor
membranes (1). It has been proposed that this difference
reflects the distinct functions of the donor membranes as
producers of vesicles and the acceptor membranes as fu-
sion partners for vesicles (1). To determine whether this is
a uniform feature of transport throughout the Golgi com-
plex, the sensitivity of each donor and acceptor compart-
ment to pretreatment with NEM was analyzed. As shown
in Table I, the donor compartment in the medial assay has
a significantly higher sensitivity to irreversible inhibition
by NEM than the acceptor membranes, as previously re-
ported (1). In contrast, the donor membranes in the trans
and TGN assays are not only less sensitive to inhibition by
NEM, but their NEM sensitivity is also indistinguishable
from that of the acceptor membranes.
 These distinctions between assays could reflect mecha-
nistic differences between transport to early and late Golgi
compartments. It is also possible, however, that they are a
function of the cell line from which the donor membranes
were prepared. To test this hypothesis, we analyzed the
characteristics of NSF-dependent transport to the medial-
Golgi using donor membranes derived from CHO Lec 8
and Lec 2 cells (see Materials and Methods). In both cases,
the NSF-dependent rate of transport, the inhibition of the
NSF-dependent transport by GTPgS, and the NEM sensi-
tivity of the donor membranes were identical to Lec 1 do-
nor membranes (data not shown). We also used donor
membranes derived from CHO Lec 2 cells to measure
NSF-dependent transport to the trans-Golgi. The charac-
teristics of transport matched those of Lec 8 donor mem-
branes (data not shown). We conclude that the differences
between the assays are characteristic of the specific inter-
compartmental transfer step that is measured in each as-
say, and not the individual donor cell lines or glycosylation
reactions.
Transport to trans-Golgi and TGN Is Inhibited by 
GTPgS at Low Cytosol Concentrations
One possible explanation for the differences between the
assays might be that the medial assay measures direct fu-
sion of donor and acceptor compartments, whereas trans-Happe and Weidman In Vitro Transport to Distinct Golgi Cisternae 515
port in the trans and TGN assays might be coatomer vesi-
cle dependent. If this were true, the lowest concentrations
of cytosol (the source of ARF and coatomers) that drive
transport to the trans and TGN compartments should be
sufficient to observe inhibition of transport by GTPgS since
vesicles made with ARF-GTPgS are unable to shed their
coats and fuse (54). We therefore examined the cytosol de-
pendence of inhibition by GTPgS in each assay. All three
assays were inhibited by GTPgS, but each assay varied in
the extent of inhibition and concentration of cytosolic pro-
teins required to cause this inhibition (Fig. 1). As previ-
ously reported (35), transport in the medial assay showed a
slight stimulation at low levels of cytosol and was incom-
pletely inhibited by GTPgS at the highest concentrations
of cytosol that could be tested (Fig. 1 A). The trans assay
also exhibited stimulation at low cytosol levels but was more
sensitive to GTPgS inhibition at intermediate levels of cy-
tosol than the medial assay (Fig. 1 B). In contrast, the TGN
assay was significantly inhibited by GTPgS at cytosol con-
centrations well below those necessary to drive optimal
transport (Fig. 1 C). The IC50 for GTPgS in all three assays
was the same (0.3 mM), however, suggesting that the same
GTP-binding protein may be the target for inhibition.
These data raised the possibility that there is a transition
from nonvesicular to vesicular transport as the donor/ac-
ceptor compartments are shifted to the trans side of the
Golgi stack.
ARF-depleted Cytosol Supports In Vitro Transport 
throughout the Golgi Stack
If transport to the trans-Golgi and/or TGN requires coated
vesicles, then ARF should be the primary GTPgS-sensitive
component and should also be required for transport in
these assays (55). We therefore tested for an ARF require-
ment using ARF-depleted cytosol. No antibodies currently
exist that are capable of immunoprecipitating native ARFs
from cell extracts (56). The chromatographic method for
preparing ARF-depleted cytosol of Taylor et al. (56) re-
sulted in loss of transport factor(s), other than ARF, that
were necessary to reconstitute transport to late Golgi com-
partments in these assays (data not shown; see Discus-
sion). We therefore developed a modified chromatography
protocol that more selectively removed all detectable iso-
forms of ARF from cytosol, while retaining transport fac-
tors needed in all three assays (see Materials and Methods).
Briefly, cytosolic protein was applied to an anion ex-
change column in 20 mM KCl buffer containing EDTA,
eluted first with 65 mM KCl buffer containing Mg21, and
then with 500 mM KCl buffer (Fig. 2 A). The unbound
protein and the 500 mM eluate were combined, concen-
trated, and desalted to produce ARF-depleted cytosol.
Recombining this ARF-depleted cytosol with the concen-
trated ARF-containing 65 mM KCl eluate produced a
fully reconstituted cytosol. Western blot analysis revealed
that ARF-depleted cytosol prepared by this method is
substantially free of ARF (.98%, Fig. 2 B). Recovery of
ARFs in the 65 mM KCl eluate was z50%, and total pro-
tein recovery was 60–80%. As previously described (56),
Table I. Comparison of In Vitro Transport to Three Distinct Golgi Compartments
Transfer step
Cis to medial Medial to trans Trans to TGN
Donor mutant Lec1 Lec 8 Lec 2
Donor defect GlcNAc transferase UDP-Galactosyl translocase CMP-sialic acid translocase
Substrate UDP-[3H]GlcNAc UDP-[3H]Gal CMP-[3H]SA
Characteristics of transport
T1/2 transport and glycosylation (min) 25 40 50
T1/2 transport only (min) 12 20 37
Donor, IC50 (mM NEM) 0.2 0.8 0.9
Acceptor, IC50 (mM NEM) .1.0 0.8 0.9
The kinetics of transport-coupled glycosylation were measured by stopping the transport reaction after various lengths of time at 37°C and placing on ice. The kinetics of transport
independent of glycosylation were determined using two-stage kinetic assays (see Materials and Methods). The IC50 for inactivation by NEM was determined by pretreating either
donor or acceptor membranes with 0–2 mM NEM for 15 min at room temperature, as described in Materials and Methods.
Figure 1. Transport to late
Golgi compartments is inhib-
ited by GTPgS at low cytosol
concentrations. Inhibition of
transport by GTPgS in the
medial ( A ),  trans ( B ), and
TGN (C) assays was assessed
by titrating CHO cytosol into
each assay in the presence of
2  mM GTPgS (closed sym-
bols) or in its absence (open
symbols). Data are represen-
tative of more than 10 indi-
vidual experiments in each
assay with different cytosol
preparations. The Journal of Cell Biology, Volume 140, 1998 516
ARFs were virtually undetectable in the Golgi membrane
fractions (Fig. 2 C). By comparison with Western blots of
purified ARFs (not shown), we estimate that the concen-
tration of ARFs in unfractionated, reconstituted, and ARF-
depleted bovine brain cytosols are z160, 84, and ,3 mg/ml,
respectively. 
Fig. 3 shows that reconstituted cytosol (recombination
of ARF-depleted and ARF-containing pools; closed cir-
cles) is able to fully reconstitute transport compared with
unfractionated cytosol (open circles) in all three assays.
This demonstrates that transport factors were not lost or
inactivated by the chromatographic procedure, although
factor(s) that inhibit the glycosylation of VSV-G protein
at high cytosol concentrations were frequently lost (com-
pare unfractionated versus reconstituted cytosol). Signifi-
cantly, ARF-depleted cytosol (open squares) is essentially
indistinguishable from reconstituted cytosol in all three as-
says. The slightly greater volume of reconstituted and ARF-
depleted cytosols needed to reach the plateau level of trans-
port observed with unfractionated cytosol is likely to be
due to the incomplete recovery of protein after chroma-
tography and concentration. These data demonstrate that
maximal transport can be achieved in the absence of ARF
in all three assays. We conclude that ARF is not required
to observe in vitro transport at any level within the Golgi
stack. 
We also determined whether the removal of ARFs ren-
dered the assays insensitive to inhibition by GTPgS. As
shown in Fig. 4, transport with reconstituted cytosol (open
circles) remained sensitive to inhibition by GTPgS (closed
circles) in all three assays, whereas transport with ARF-
depleted cytosol (open squares) was insensitive to GTPgS
(closed squares), even at high cytosol concentrations. With
some preparations of ARF-depleted cytosol, transport in
the medial and trans assays was actually slightly stimulated
by GTPgS (not shown). A small amount of inhibition by
GTPgS was occasionally observed in the TGN assay (Fig.
4  C). This inhibition did not increase with increasing
amounts of cytosol, suggesting that the GTPgS-sensitive
inhibitory component is membrane associated. Thus, re-
moval of ARFs from cytosol correlates with loss of cyto-
sol-dependent GTPgS inhibition, suggesting that ARFs
are responsible for the inhibition observed in all three
transport assays.
To verify this, we examined the GTPgS sensitivity of
each assay upon addition of purified recombinant myris-
toylated ARF1 (myr-rARF1). As shown in Fig. 5, inhibi-
tion is restored in all assays by addition of myr-rARF1 to
ARF-depleted cytosol in the presence of GTPgS (black
bars). Since only 5.7% of the myr-rARF1 is actually myris-
toylated (Kahn, R., personal communication), the concen-
trations of myr-rARF1 that cause inhibition are compara-
ble to the concentration of endogenous ARFs in an assay
containing 1–4 ml of CHO cytosol (1.6–6.4 ug/ml final at 40
ng ARF per ml of cytosol; reference 56). Addition of non–
myr-rARF1 (hatched bar) had no effect, as expected, since
myristoylation is required for the biological activities of ARF
(6, 20). For a given amount of myr-rARF1, inhibition was
consistently least in the medial assay and greatest in the TGN
assay, correlating with the differential cytosol dependence
of GTPgS inhibition (Fig. 1). These data confirm that the
cytosolic GTPgS-sensitive inhibitory component in all three
assays is ARF. ARF, therefore, is not directly required to
support in vitro Golgi transport, but rather exerts a nega-
tive effect when constitutively activated by GTPgS. 
ARF-depleted Cytosol Does Not Support Golgi Coated 
Vesicle Formation
We have previously shown that ARF-depleted cytosol pre-
pared by the method of Taylor et al. does not support
coated bud and vesicle formation on Golgi membranes
(56). Since we have modified that original procedure to re-
tain additional factors required for transport to late Golgi
compartments, we determined whether this ARF-depleted
cytosol is also deficient in coated bud formation. High-res-
olution images from replicas of quick-frozen, freeze-dried
Golgi membranes reveal that Golgi incubated in vitro with
unfractionated cytosol (Fig. 6 A) or reconstituted cytosol
Figure 2. ARF can be removed from cytosol in one ion-exchange
chromatography step. (A) Bovine brain cytosol was fractionated
by chromatography on Fast-Flow Q, as described in Materials
and Methods. Closed circles indicate the protein elution profile.
The dashed line represents the salt concentration of each elution
buffer. Additional buffer components are indicated below the
protein peaks. (B) Western blot of unfractionated cytosol, the
ARF-containing pool, and the ARF-depleted cytosol probed with
anti-ARF monoclonal 1D9 antibody, as described in Materials
and Methods. Volume equivalents applied to the gel are indi-
cated below each sample. Data are representative of four inde-
pendent ARF-depleted cytosol preparations. (C) Western blot of
isolated donor and acceptor Golgi membranes (0.5 mg/ml) and
unfractionated cytosol, probed with anti-ARF monoclonal 1D9.
The blot was overexposed to reveal a slight signal at highest level
of acceptor Golgi. No signal was observed with the different do-
nor membranes used in each assay. Only the medial donor Golgi
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(not shown) exhibit abundant buds and vesicles with a
punctate surface coating. In contrast, Golgi incubated with
ARF-depleted cytosol exhibit few buds or vesicles, and
those few that are observed lack the distinctive punctate
surface texture of coated buds (Fig. 6 B). As expected, ad-
dition of recombinant myr-rARF1 (Fig. 6 C), but not non–
myr-rARF1 (Fig. 6 D), to ARF-depleted cytosol restores
formation of coated buds on Golgi cisternae. Quantitative
analysis demonstrates that coated bud and vesicle density
is reduced 50% in incubations containing reconstituted cy-
tosol (Fig. 7 A, black bars), which contains only half as
much ARF as the unfractionated cytosol (Table II). De-
pletion of ARF reduced the coated bud and vesicle density
z15-fold relative to unfractionated cytosol (Fig. 7 A, black
bars), the same level normally observed with unincubated
membranes (58). In contrast, there is a low density of un-
coated buds and vesicles in all samples that is independent
of the ARF concentration (Fig. 7 A, hatched bars). The tips
of tubules extending from cisternae make up the majority
of these uncoated buds (.85%). These are likely to have
been present at the beginning of the incubation since they
are also seen on unincubated membranes (56; not shown).
Membranes incubated with ARF-depleted cytosol pre-
pared by the method of Taylor et al. were previously shown
to be morphologically indistinguishable from unincubated
membranes (56). This was also the case with many of the
cisternae incubated with ARF-depleted cytosol prepared
by the new method. However, a subset of the cisternae did
exhibit noticeably larger fenestrae and longer blunt-ended
tubules extending from the periphery (Fig. 6 B and Table
II). Qualitative analysis revealed that the fraction of cister-
nae exhibiting large fenestrae (.100 nm diameter) in-
creased more than twofold upon depletion of ARF (Fig. 7 B).
This tendency was further exacerbated by inclusion of ex-
cess non–myr-rARF1 and reversed by inclusion of myr-
rARF1. Enlargement of fenestrae was accompanied by an
increase in the average area encompassed by each cisterna
(Table II). Depletion of ARF alone did not significantly
increase the number of fenestrae (Table II) or blunt-ended
tubules per cisternae (Fig. 7 A, hatched bars) but did in-
crease the length of the tubules (Table II). This suggests
that the enlarged fenestrae arose by growth of tubules en-
closing preexisting fenestrae. In contrast, inclusion of ex-
cess non–myr-rARF1 increased both the size and number
of fenestrae per cisternae but also decreased the number
of cisternae per image (Table II). This might indicate that
residual endogenous ARF suppresses tubule elongation
and that competitive inhibition by non–myr-rARF1 leads
to further elongation and membrane destabilization. These
results confirm that relatively high levels of myristoylated
ARF are needed to sustain coated bud formation on Golgi
membranes, but the possibility that a low level of myris-
toylated ARF may also be necessary to maintain the com-
pactness and integrity of the fenestrated edges of cisternae
is also raised. 
Figure 3. ARF-depleted cy-
tosol fully supports transport
in all three in vitro assays.
Unfractionated bovine brain
cytosol (open circles), recon-
stituted cytosol (closed cir-
cles), and ARF-depleted cy-
tosol (open squares) were
titrated into the medial (A),
trans (B), and TGN (C) as-
says. A cytosol equivalent is
the volume of sample equal
to 1 ml of unfractionated con-
trol cytosol after taking into
account volume changes af-
ter chromatography. The
protein concentration of con-
trol cytosol was 12.1 mg/ml.
Data are representative of
two independent ARF-
depleted cytosol preparations. 
Figure 4. ARF depletion
prevents cytosol-dependent
inhibition by GTPgS. The
ability of GTPgS to inhibit
transport with bovine brain
reconstituted cytosol (circles)
or ARF-depleted cytosol
(squares) was determined by
titrating increasing cytosol
equivalents into the medial
(A), trans ( B ), or TGN (C)
assays in the presence of 2
mM GTPgS (closed symbols)
or in its absence (open sym-
bols). Data are representa-
tive of two independent
ARF-depleted cytosol prepa-
rations.The Journal of Cell Biology, Volume 140, 1998 518
A Shift in Mechanism Is Not Detected upon
Removal of ARF
Since depletion of ARF not only blocks coated vesicle for-
mation but increases the tendency for elongated tubules
and fenestrae to form on cisternae, it is possible that the
removal of ARF causes the mechanism of transport to shift
from vesicular to nonphysiological uncoupled fusion of
Golgi membranes, as others have suggested (18). In this
case, it would be expected that the distinctive properties of
each transport assay would converge on a common value
that is characteristic of uncoupled fusion. We therefore ex-
amined the effect of removing ARF on the unique proper-
ties of each assay, the rate of transport and the sensitivity
of the donor membranes to inactivation by NEM. As shown
in Fig. 8, when the rate of transport was measured inde-
pendently of the rate of glycosylation using a two-stage in-
cubation, each assay retained its characteristic kinetics of
transport upon depletion of ARF. In addition, the donor
membranes in the medial assay remained significantly more
Figure 5. Recombinant ARF1 restores GTPgS sensitivity to
ARF-depleted cytosol. Unfractionated bovine brain cytosol (5 ml)
and ARF-depleted cytosol (5-ml equivalents) were tested in the
medial (A), trans (B), and TGN (C) assays in the presence of 2 mM
GTPgS (solid bars) or in its absence (open bars). The indicated
amounts of myr-rARF1 (5.7% myristoylated) or non–myr-rARF1
(hatched bar) were titrated into the assay. Data are a combina-
tion of two independent experiments. The maximum counts per
minute for unfractionated cytosol were 7,764 6 184 in the medial
assay, 4,076 6 64 and 2,960 6 203 in the trans assay, 3,030 6 204
and 3,389 6 48 in the TGN assay. The maximum counts per
minute for ARF-depleted cytosol were 4,866 6 114 and 8,850 6 15
in the medial assay, 2,184 6 323 and 1,881 6 15 in the trans assay,
and 2,981 6 153 and 2,498 6 31 in the TGN assay. The acceptor
membranes used in these experiments were different from the prep-
aration used in Fig. 4 and exhibit less cytosol-independent inhibi-
tion of transport to the TGN by GTPgS (compare Figs. 4 C and 5 C).
Figure 6. Golgi coated bud formation is blocked by ARF deple-
tion and restored by purified ARF. Replicas of Golgi membranes
after a 15-min transport incubation were prepared as described in
Materials and Methods. The transport reaction mixtures con-
tained (A) unfractionated bovine brain cytosol (2.4 mg/ml); (B)
ARF-depleted bovine brain cytosol (2.4 mg/ml); (C) ARF-
depleted cytosol plus myr-rARF1 (120 mg/ml, 5.7% myristory-
lated); and (D) ARF-depleted cytosol plus non–myr-rARF1 (120
mg/ml). Boxed areas are presented at higher magnification in the
panels on the right side of the figure, illustrating the punctate sur-
face coating on Golgi buds in A and C. Buds in B lack this punc-
tate coating and have a granular texture similar to the surround-
ing tubules. Bars, 0.5 mm.Happe and Weidman In Vitro Transport to Distinct Golgi Cisternae 519
sensitive to NEM pretreatment than the acceptor mem-
branes even in the absence of ARF (Fig. 9 A). Moreover,
the NEM sensitivity of the donor and acceptor membranes
in the trans and TGN assays was also unchanged by re-
moving ARF (Fig. 9, B and C). Thus, the distinctive prop-
erties of each assay remain unchanged upon ARF deple-
tion, suggesting that there is no change in the mechanism
of transport. It therefore seems likely that vesicles are not
required for in vitro transport even when they are formed.
Discussion
The molecular details of transport within the Golgi com-
plex have largely come from the analysis of a system that
reconstitutes a single transport step between cis and me-
dial compartments of the Golgi complex. Although it has
generally been assumed that the mechanism of transport is
essentially the same throughout the Golgi, this has never
been rigorously examined. Here, we have used a compara-
tive analysis of three different cell-free intra-Golgi trans-
port assays to investigate the role of vesicles in antero-
grade transport between different compartments of the
Golgi complex. The results of our analysis provide novel
insights into the complexity of intra-Golgi transport, and
evidence in support of the view that, at least in vitro, trans-
port throughout the Golgi complex is vesicle independent.
The In Vitro Assays Reconstitute Transport to Distinct 
Golgi Compartments
The cell-free assays for transport to the medial-Golgi,
trans-Golgi, and TGN exhibit similar overall requirements
for optimal reconstitution of transport. This was expected
given the fundamental conservation of transport compo-
nents throughout the secretory pathway (19, 49, 50). Nev-
ertheless, each assay apparently has unique requirements
for cytosolic proteins. Cytosol fractionated by the method
of Taylor et al. (56) was consistently incapable of reconsti-
tuting transport in one and/or the other of the two assays
that measure transport to late Golgi compartments, even
though this cytosol was functional in the medial assay. This
observation is consistent with the finding that sequential
transport steps from the ER to the TGN in permeabilized
cells exhibit differential requirements for cytosolic factors
(13). As further evidence that each assay reconstitutes
transport between distinct compartments, our data show
that the transport rate, the cytosol dependence of GTPgS
inhibition, and the donor membrane NEM sensitivity are
also unique for each assay. Moreover, these characteristics
are independent of the rate of glycosylation and the source
of donor membranes. It thus appears that each in vitro
transport assay reconstitutes a distinct compartment-spe-
cific transport step within the Golgi complex. 
ARF and Vesicles Are Dispensable for In Vitro 
Transport throughout the Golgi Stack
Using an improved procedure for removing endogenous
ARFs from cytosol, we have demonstrated that in vitro
transport to the medial-Golgi, trans-Golgi, and TGN can
be fully reconstituted with cytosol that is substantially de-
pleted of endogenous ARFs. ARF-depleted cytosol was
able to drive transport to nearly the same maximum level
attained with reconstituted or unfractionated cytosol, at
nearly the same volume equivalents. Nevertheless, ARF-
depletion reduced the density of coated vesicles on Golgi
membranes 15-fold relative to unfractionated cytosol. Thus,
there is no apparent correlation between coated bud and
vesicle formation on Golgi membranes and in vitro trans-
port at any level of the stack. 
A new finding in this study is that ARF-depletion also
resulted in the elongation of fenestrae and blunt-ended tu-
bules on a subset of Golgi cisternae, apparently without
Figure 7. Depletion of ARF decreases the density of coated buds
and vesicles and increases the proportion of cisternae with large
fenestrae. (A) The densities of buds and vesicles with a smooth
surface (uncoated) or a distinctive punctate coating (coated) were
determined from electron micrographs as described in Materials
and Methods. Blunt-ended tubules made up greater than 85% of
the observed uncoated buds and vesicles in all images. Error bars
represent the standard error of the mean, and the numbers in pa-
rentheses indicate the number of micrographs analyzed. (B) The
average size of cisternal fenestrae was estimated from the elec-
tron micrographs. Numbers in parentheses above the bars repre-
sent the total number of cisternae. Direct measurement of the
maximum diameter of the fenestrae on five micrographs repre-
sentative of each size class revealed that fenestrae scored as
small, medium, and large had average diameters (6SD) of 42 6
25 nm (n 5 32), 84 6 31 nm (n 5 36), and 180 6 80 nm (n 5 33),
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significantly increasing their numbers. A similar “tubular-
ization” occurs when Golgi membranes are incubated with
ATP in the absence of any cytosol (58). Tubularization in
the absence of cytosol is accompanied by the loss of a
granular coating normally observed on the periphery of
cisternae. We proposed that this granular coating, which
we call a type II coat, might function to stabilize curved
membrane edges, and that its loss leads to destabilization
and rearrangements within the preexisting tubular net-
works that enclose the fenestrae (58). The tubular cister-
nae produced during incubations with ARF-depleted cytosol,
however, seem to largely retain this peripheral coating (Fig.
7, B and D). Significantly, such tubularization was not ob-
served with ARF-depleted cytosol prepared by the method
of Taylor et al. (56). The primary difference between ARF
depletion methods is the preservation of additional cyto-
solic factor(s) in the new protocol that are specifically re-
quired for transport to late Golgi compartments. It is thus
possible that the tubularization observed here is of a dif-
ferent nature from that occurring in the absence of cytosol
and requires specific cytosolic factor(s), in addition to de-
pletion of ARF. A cytosolic protein complex that induces
the formation of long Golgi tubules has, in fact, been de-
scribed (3). The cytosolic factor(s) required for this activ-
ity may, however, be distinct from those required for trans-
port in these assays since tubularization had no detectable
effect on the characteristics of transport. 
Table II. The General Features of Cisternae after an In Vitro Transport Incubation with or without ARF
Cytosol Concentration of ARF Cisternae per micrograph Percent with long tubules Area per cisternae Fenestrae per cisterna
mg/ml mm2
Control 40 2.3 6 0.3 (30) 20 0.38 6 0.3 (67) 7.4 6 1.6 (67)
Reconstituted 22 2.4 6 0.3 (23) 19 0.39 6 0.2 (53) 9.1 6 2.0 (53)
ARF-depleted ,1.4 2.0 6 1.2 (38) 37 0.43 6 0.2 (71) 9.6 6 1.4 (71)
ARF-depleted 1, 1.4 (120) 1.5 6 0.7 (22) 55 0.55 6 0.6 (34) 15.4 6 2.9 (34)
non–myr-rARF1
ARF-depleted 1 8.2 (112) 2.5 6 1.3 (43) 12 0.39 6 0.2 (73) 6.0 6 0.9 (73)
myr-rARF1
The concentration of myristoylated ARF in each in vitro incubation was estimated from titrations of the respective cytosols on Western blots, as shown in Fig. 3, where the detec-
tion limit was 80 ng ARF. The concentrations of myr-rARF1 and non–myr-rARF1 (in parentheses) were calculated from the protein concentration of the purified recombinant
ARFs and the fraction that was myristoylated (5.7%). Cisternae per micrograph, area per cisternae, and fenestrae per cisternae were measured as described in Materials and Meth-
ods and are reported as the average plus or minus standard error, with the number of micrographs or cisternae analyzed in parentheses. The number of blunt-ended tubules per cis-
ternae was similar in all samples. The percent with long tubules represents the fraction of cisternae in which these tubules were .100 nm in length.
Figure 8. Depletion of ARF
does not change the rate of
transport. The rate of trans-
port (independent of glyco-
sylation) was assessed in the
medial ( A ),  trans ( B ), and
TGN (C) assays in the pres-
ence of ARF (unfractionated
cytosol,  open circles) or the
absence of ARF (closed cir-
cles) in two-stage assays, as
described in Materials and
Methods. Each point in B
and C represents the mean
value of two or five indepen-
dent experiments, respec-
tively, using 3–7.5-ml equiva-
lents of cytosol per assay.
The maximum amounts of
3H incorporated into VSV-G
protein were 9,735, 11,682 6
2,159, and 3,985 6 980 cpm in
for the medial, trans, and
TGN assays, respectively. 
Figure 9. ARF depletion has
no effect on the NEM sensi-
tivity of donor and acceptor
membranes. Donor (open
symbols) or acceptor (closed
symbols) membranes were
pretreated separately with
NEM, as described in Mate-
rials and Methods. The me-
dial (A), trans (B), and TGN
(C) assays were analyzed
with either unfractionated
cytosol containing ARF (cir-
cles) or ARF-depleted cyto-
sol (squares) at 2.5-ml equiva-
lents per assay. The control
values for assays with unfrac-
tionated cytosol were 6,724
6 1, 11,457 6 923, and 3,461
6 123 cpm 3H incorporated
into VSV-G protein in the
medial, trans, and TGN as-
says, respectively. For the
ARF-depleted cytosol, they
were 5,433 6 298, 7,750 6
354, and 2,562 6 37 cpm.Happe and Weidman In Vitro Transport to Distinct Golgi Cisternae 521
Although depletion of ARF promoted growth of fenes-
trae and tubules on a subset of Golgi cisternae, no bio-
chemical evidence was obtained to support the hypothesis
that there is a switch in the mechanism of transport from
vesicular to unregulated cisternal fusion at any level of the
stack. Since each assay has its own distinctive characteris-
tics, unregulated fusion of membranes in the absence of
ARF might be reasonably expected to cause a change, if
not a convergence, in these properties. The only biochemi-
cal change detected with ARF-depleted cytosol, however,
was loss of inhibition by GTPgS. The rate of transport, the
maximal extent of transport, and the NEM sensitivity of
the membranes were completely unaffected by removing
ARF. These findings favor the interpretation that in vitro
transport normally occurs by a vesicle-independent mech-
anism, even when vesicles can be formed.
Constitutive Activation of ARF Differentially Inhibits 
Each Transport Step
Although not required for in vitro Golgi transport, consti-
tutively activated ARF is clearly an inhibitor of transport
at all levels of the Golgi stack. The characteristics of this
inhibition, however, are not uniform in each assay. Only
partial inhibition is observed in the medial assay and only
when the system is saturated with cytosol. In contrast, in-
hibition of the TGN assay is substantial at the minimal lev-
els of cytosolic protein required for transport. Although it
is possible that each assay is preferentially inhibited by dif-
ferent ARF isoforms, the differential sensitivity to GTPgS
can be reproduced by recombinant myristoylated ARF1
alone. Each assay might, thus, use compartment-specific
factors that have differential affinity for ARF, such as ARF
GDP–GTP exchange factors or ARF effector proteins. If
inhibition is solely due to sequestration of cisternal mem-
brane into coated vesicles, as we have proposed for the
medial assay (58), this differential sensitivity seems to run
counter to the observation that coatomer binding is pre-
dominantly on the cis rather than trans side of the stack
(39). ARF-induced binding of the Golgi-specific adaptor
protein, AP-I, could provide a similar block to transport
on the trans side of the stack. This seems unlikely, how-
ever, since in vitro studies suggest that, if anything, low
concentrations of ARF-GTPgS are more effective at re-
cruiting coatomer than AP-1 (52, 57). Studies are under-
way to determine the mechanisms underlying this differ-
ential cytosol dependence of GTPgS-induced inhibition in
each assay.
Donor and Acceptor Membrane Asymmetry Is Not 
Related to Vesicular Transport 
It has long been known that the donor and acceptor mem-
branes in the medial assay differ markedly in their stability
to various treatments (1). This biochemical asymmetry has
been proposed to reflect the need for different sets of pro-
teins for the processes of vesicle formation and vesicle fu-
sion on the donor and acceptor membranes, respectively
(1). Our data show that the differential sensitivity of donor
and acceptor membranes to inactivation by NEM at 37°C
is completely independent of vesicle formation in the me-
dial assay. Moreover, the donor compartments in the trans
and TGN assays are considerably less sensitive to NEM-
inactivation and have the same sensitivity as the acceptor
compartments. Since the donor and acceptor compart-
ments in these assays unambiguously reside within the Golgi
complex, it seems likely that their NEM sensitivity is a char-
acteristic of Golgi-specific compartments. Indeed, the IC50
for NEM inhibition in these assays is similar to the EC50
for NEM-induced permeabilization of Golgi membranes
(60). The unique NEM sensitivity of donor membranes in
the medial assay might thus indicate that the donor in this
assay corresponds to a non-Golgi compartment, perhaps
elements of the ERGIC (56). These intermediates might
be able to fuse with the cis acceptor Golgi compartment,
where incorporation of GlcNAc into VSV-G protein can
also occur in CHO cells (51). The activity of the ERGIC as
donor in this particular assay can now be directly tested.
Possible Mechanisms of ARF-independent In Vitro 
Golgi Transport
If in vitro Golgi transport does not involve ARF or vesicle
carriers, then by what mechanism do proteins move be-
tween cisternae in these assays? One possible explanation
is that the assays reconstitute only lateral fusion of biosyn-
thetically identical donor and acceptor cisternae (cis–cis,
medial–medial, etc.; reference 36), rather than anterograde
transport between distinct cisternae. For example, because
donor membranes in the medial assay lack GlcNAc trans-
ferase I, both the VSV-G protein in the cis and medial
compartments of the donor membranes lack GlcNAc and
are thus suitable substrates for GlcNAc transferase I in the
medial acceptor compartment. Lateral fusion between
medial donor and medial acceptor compartments would,
therefore, result in addition of [3H]GlcNAc to VSV-G pro-
tein carbohydrates. Similarly, lateral fusion in all of these
in vitro assays could give rise to a transport signal. In
spite of this, substantial NSF-dependent incorporation of
[3H]GlcNAc occurred when Lec 8 and Lec 2 donor Golgi
were substituted for Lec 1 donor Golgi in the medial assay.
If only lateral transport between medial compartments
was reconstituted, membrane fusion (i.e., NSF) would not
be required to observe glycosylation because Lec 8 and
Lec 2 membranes contain active GlcNac transferase I in
the medial-Golgi. It thus appears that a significant portion,
if not all, of the transport detected in the medial assay is
anterograde. Additional studies verifying and extending
this conclusion to transport throughout the Golgi stack
will be reported elsewhere (Cairns, M., S. Happe, and P.
Weidman, manuscript in preparation).
An alternative hypothesis is that transport could occur
between biosynthetically distinct donor and acceptor Golgi
compartments by fusion of peripheral Golgi tubules (59).
For example, the tip of a tubule on a donor cisterna could
potentially target to an acceptor cisterna and fuse in an
NSF-dependent reaction. Although the de novo formation
and/or scission of these Golgi tubules might require ARF
and coat proteins (59), the actual fusion event would de-
pend only on the presence of blunt-ended tubules with the
requisite components for targeting and fusion. Elongation
of fenestrae and tubules might also have no effect on trans-
port, if the number of blunt-ended tubules competent for
transport does not change. On the other hand, constitutive
activation of ARF might result in irreversible coating ofThe Journal of Cell Biology, Volume 140, 1998 522
these tubule tips, an increased frequency of tubule scission
reactions (59), and/or sequestration of potential fusion sites
(58). This could cause inhibition of in vitro transport, even
though ARF is not directly required for transport per se. 
Consistent with this model, isolated Golgi cisternae ex-
hibit a low but relatively constant number of uncoated
buds at the tips of peripheral tubules, and tubular connec-
tions between cisternae are commonly seen (Figs. 6 and 7
A). If the uncoated tips of tubules on isolated Golgi are
the primary active elements in in vitro transport, then it
would be reasonable to expect that the characteristics of
transport (i.e., targeting and fusion) would remain con-
stant, independent of whether new coated buds form or tu-
bules elongate. Fusion between distinct compartments
could, however, use a subset of compartment-specific tar-
geting and/or fusion components, accounting for the dif-
ferent characteristics of each transport assay. An alterna-
tive explanation for the unique characteristics of transport
to early and late Golgi compartments might also be that
the assays are measuring different phenomena, such as fu-
sion of ERGIC with early Golgi compartments in the me-
dial assay versus intra-Golgi transport by tubules in the
trans and TGN assays.
A final possibility that cannot be excluded at present is
that transport could involve the targeted fusion of Golgi
membrane fragments that are produced during cell ho-
mogenization. These fragments might fuse with each other
or with cisternae. This might explain the lack of correla-
tion between changes in cisternal morphology and the bio-
chemical properties of transport. If this is the case, our
data indicate that compartmental specificity is retained,
and that these new in vitro assays will be useful for the
identification of compartment specific components in tar-
geting and fusion. 
What Is the Relationship between In Vitro and In Vivo 
Intra-Golgi Transport?
A long standing issue in the use of in vitro systems to study
transport processes has been the question of how faithfully
the in vitro system reconstitutes the in vivo process. This
has been particularly true in the case of transport within
the Golgi complex, where neither in vitro nor in vivo stud-
ies have been able to unambiguously define the role of
ARF and coatomer vesicles in secretory protein transport.
The available evidence indicates that ARF and coatomer
are essential for maintenance of Golgi integrity (12, 25) and
for retrograde transport from the intermediate compart-
ment and Golgi to the ER (11, 22, 27, 33). Golgi enzymes
also seem to undergo retrograde transport within the stack
(7, 24, 26, 29, 61), although the role of coatomer vesicles in
this process has not been established. The possibility that
coatomer vesicles are exclusively retrograde carriers has
lead to a revival of the cisternal maturation model as an al-
ternative to the classical vesicular model for anterograde
intra-Golgi transport (4, 23, 34). In the cisternal matura-
tion model, cargo protein is transported forward in cister-
nae that “mature” sequentially into cis, medial, and trans
cisternae, as a consequence of the retrograde vesicular
transport of Golgi enzymes (23). Upon reaching the TGN,
the cargo is packaged into vesicles for transport to the cell
surface, and the Golgi enzymes recycle in vesicles to the
trans cisterna. The possibility that coatomer vesicles medi-
ate both anterograde transport through the Golgi com-
plex, as well as retrograde transport to the ER, has been
proposed from the recent finding that retrograde and an-
terograde cargo within the Golgi segregate into distinct
populations of coatomer-coated buds and vesicles (41). 
How can these observations be reconciled with the in
vitro transport data, where coated vesicles appear to be
entirely dispensable for intra-Golgi transport? There is
clearly some fidelity in the reconstitution, since there is a
requirement for NSF, presumably also SNAPs and SNAREs,
and one or more compartment-specific cytosolic factors.
Directionality also seems to be preserved. If ARF and
coatomer mobilize protein for anterograde transport in vivo
(41), either in vesicles or in tubules (37, 38, 59), our data
suggest that this function is not reconstituted in these cell-
free assays in spite of the fact that coated buds are formed.
There is a possibility that only protein mobilized by ARF
and coatomer in vivo is competent to be transported in
vitro. In this case, the blunt-ended tubules on isolated
Golgi, or fragments thereof, are reasonable candidates for
such ARF-independent transport intermediates. The seg-
regation of anterograde cargo into coatomer buds in vivo
(41) might thus represent mobilization into tubules, rather
than vesicles, as previously suggested (59). Alternative ap-
proaches will clearly be needed to resolve the potential
role(s) of ARF and coatomers in tubule morphogenesis
and anterograde transport.
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